Literature DB >> 30918873

Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity.

Rai Ajit K Srivastava1,2.   

Abstract

Energy imbalance resulting from high calorie food intake and insufficient metabolic activity leads to increased body mass index (BMI) and sets the stage for metabolic derangement influencing lipid and carbohydrate metabolism and ultimately leading to insulin resistance, dyslipidemia, and type 2 diabetes. 70% of cardiovascular disease (CVD) deaths occur in patients with diabetes. Environment-induced physiological perturbations trigger epigenetic changes through chromatin modification and leads to type 2 diabetes and progression of nonalcoholic fatty liver disease (NAFLD) and CVD. Thus, in terms of disease progression and pathogenesis, energy homeostasis, metabolic dysregulation, diabetes, fatty liver, and CVD are interlinked. Since advanced glycation end products (AGEs) and low-grade inflammation in type 2 diabetes play definitive roles in the pathogenesis of liver and vascular diseases, a natural checkpoint to prevent diabetes and associated complications appears to be the identification and management of prediabetes together with weight management, since 70% of prediabetic individuals develop diabetes during their life time, and every kg of weight increase is associated with up to 9% increase in diabetes risk. A good proportion of diabetes and obesity population have fatty liver that progresses to non-alcoholic steatohepatitis (NASH) and cirrhosis, and increased risk of hepatocellular carcinoma. Diabetes and NASH both have elevated oxidative stress, impaired cholesterol elimination, and increased inflammation that leads to CVD risk. This review addresses life-style-induced metabolic pathway derangement and how it contributes to epigenetic changes, type 2 diabetes and NASH progression, which collectively lead to increased risk of CVD.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular; Diabetes; Epigenetic; Inflammation; Life-style; NASH

Year:  2018        PMID: 30918873      PMCID: PMC6405391          DOI: 10.1007/s40200-018-0378-y

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  120 in total

1.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

Review 2.  Chromatin modifications and their function.

Authors:  Tony Kouzarides
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

Review 3.  Serum triglycerides and risk of cardiovascular disease.

Authors:  A C I Boullart; J de Graaf; A F Stalenhoef
Journal:  Biochim Biophys Acta       Date:  2011-10-08

Review 4.  Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism.

Authors:  Nobutaka Ohgami; Akira Miyazaki; Masakazu Sakai; Akihiko Kuniyasu; Hitoshi Nakayama; Seikoh Horiuchi
Journal:  J Atheroscler Thromb       Date:  2003       Impact factor: 4.928

Review 5.  Split genes and RNA splicing.

Authors:  F Crick
Journal:  Science       Date:  1979-04-20       Impact factor: 47.728

Review 6.  Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism.

Authors:  Paul Poirier; Thomas D Giles; George A Bray; Yuling Hong; Judith S Stern; F Xavier Pi-Sunyer; Robert H Eckel
Journal:  Circulation       Date:  2005-12-27       Impact factor: 29.690

Review 7.  High density lipoprotein, apolipoprotein A-I, and coronary artery disease.

Authors:  R A Srivastava; N Srivastava
Journal:  Mol Cell Biochem       Date:  2000-06       Impact factor: 3.396

8.  Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

Authors:  Ulf Risérus; Dennis Sprecher; Tony Johnson; Eric Olson; Sandra Hirschberg; Aixue Liu; Zeke Fang; Priti Hegde; Duncan Richards; Leli Sarov-Blat; Jay C Strum; Samar Basu; Jane Cheeseman; Barbara A Fielding; Sandy M Humphreys; Theodore Danoff; Niall R Moore; Peter Murgatroyd; Stephen O'Rahilly; Pauline Sutton; Tim Willson; David Hassall; Keith N Frayn; Fredrik Karpe
Journal:  Diabetes       Date:  2007-11-16       Impact factor: 9.461

Review 9.  Regulation of RAGE for attenuating progression of diabetic vascular complications.

Authors:  Myat Thu Thu Win; Yasuhiko Yamamoto; Seiichi Munesue; Hidehito Saito; Dong Han; So Motoyoshi; Tarek Kamal; Takuro Ohara; Takuo Watanabe; Hiroshi Yamamoto
Journal:  Exp Diabetes Res       Date:  2011-10-29

10.  MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.

Authors:  Meiyuan Zhang; Weilan Sun; Minghao Zhou; Yan Tang
Journal:  Sci Rep       Date:  2017-11-03       Impact factor: 4.379

View more
  6 in total

Review 1.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Authors:  Alexandra Jichitu; Simona Bungau; Ana Maria Alexandra Stanescu; Cosmin Mihai Vesa; Mirela Marioara Toma; Cristiana Bustea; Stela Iurciuc; Marius Rus; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Diagnostics (Basel)       Date:  2021-04-12

2.  New insights into the association between non-alcoholic fatty liver disease and atherosclerosis.

Authors:  Alejandro Valencia-Rodríguez; Alfonso Vera-Barajas; Beatriz Barranco-Fragoso; Deyanira Kúsulas-Delint; Xingshun Qi; Nahum Méndez-Sánchez
Journal:  Ann Transl Med       Date:  2019-12

3.  Activating transcription factor 3 is a potential target and a new biomarker for the prognosis of atherosclerosis.

Authors:  Weiwei Qin; Huiyu Yang; Gaizhen Liu; Rui Bai; Yunfei Bian; Zhiming Yang; Chuanshi Xiao
Journal:  Hum Cell       Date:  2020-09-21       Impact factor: 4.174

4.  Comparison of various steady state surrogate insulin resistance indices in diagnosing metabolic syndrome.

Authors:  Sikandar Hayat Khan; Ali Nawaz Khan; Nayyer Chaudhry; Roomana Anwar; Nadeem Fazal; Muhammad Tariq
Journal:  Diabetol Metab Syndr       Date:  2019-06-14       Impact factor: 3.320

5.  Intravital imaging of interactions between iNKT and kupffer cells to clear free lipids during steatohepatitis.

Authors:  Haitao Wang; Longjun Li; Yinling Li; Yue Li; Yeqin Sha; Shuang Wen; Qiang You; Lixin Liu; Meiqing Shi; Hong Zhou
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

6.  Ramadan and Diabetes: What About Non-Fasting Patients with Diabetes?

Authors:  Imane Motaib; Fatima-Zahra Rhmari Tlemçani; Mohamed Khalis; Soukaina Laidi; Saloua Elamari; Asma Chadli
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-28       Impact factor: 3.249

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.